Background: Sunitinib is an oral multitargeted tyrosine kinase receptor inhibitor (MTKI) used for the treatment of renal cell carcinoma. These small-molecule agents inhibit signaling through receptor tyrosine kinases such as vascular endothelial growth factor receptor, platelet-derived growth factor receptor and cytokine stem cell factor receptor, among others. Although the development of these novel molecular-targeted agents represents a substantial advance in the treatment of metastatic cancer, the spectrum of their adverse effects may be broader than initially predicted.

Method: We performed a retrospective chart review of patients who had received sunitinib and developed renal insufficiency.

Results: We describe 4 patients with renal cell carcinoma and 1 patient with transitional cell carcinoma treated with sunitinib who experienced various degrees of nephrotoxicity including hypertension, proteinuria, thrombotic microangiopathy, and acute and chronic kidney injury which resolved upon cessation of MTKI.

Conclusions: Nephrologists and oncologists should be aware of the potential for toxic renal effects, and we recommend guidelines for early recognition and treatment of these conditions in patients receiving MTKI.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000319885DOI Listing

Publication Analysis

Top Keywords

cell carcinoma
12
factor receptor
12
tyrosine kinase
8
renal cell
8
growth factor
8
receptor
5
nephrotoxicities associated
4
associated tyrosine
4
kinase inhibitors
4
inhibitors single-center
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!